<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="132834">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01939678</url>
  </required_header>
  <id_info>
    <org_study_id>2012-12</org_study_id>
    <nct_id>NCT01939678</nct_id>
  </id_info>
  <brief_title>Characterization and Role of Mutations in Sodium-phosphate Cotransporters in Patients With Calcific Aortic Valve Disease</brief_title>
  <official_title>Characterization and Role of Mutations in Sodium-phosphate Cotransporters in Patients With Calcific Aortic Valve Disease</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Hospital Orebro</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University Hospital Orebro</source>
  <oversight_info>
    <authority>Sweden: Regional Ethical Review Board</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to investigate whether mutations in genes coding for
      Na/Pi-cotransporters are associated with aortic valve calcification. A patient population
      with premature aortic valve calcification treated with aortic valve replacement will be
      screened for mutations in these specific genes. Furthermore, aortic valve tissue received
      from the operations, will be examined for the presence of Na/Pi-cotransporters, and for
      molecular characterization of the transporters.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>September 2013</start_date>
  <primary_completion_date type="Anticipated">October 2015</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Observational</study_type>
  <study_design>Observational Model: Case Control, Time Perspective: Prospective</study_design>
  <primary_outcome>
    <measure>Mutations in sodium-phosphate cotransporters in patients with calcific aortic valve disease</measure>
    <time_frame>At the time of aortic valve replacement</time_frame>
    <safety_issue>No</safety_issue>
    <description>Mutations in genes coding for Na/Pi-cotransporters</description>
  </primary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">90</enrollment>
  <condition>Calcific Aortic Valve Disease</condition>
  <biospec_retention>Samples With DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      Bloodsamples and Aortic valve samples
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        Patients with aortic valve calcification that will be treated with an aortic valve
        replacement
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients with aortic valve calcification that will be treated with an aortic valve
             replacement.

          -  Age â‰¤ 65 years.

          -  Signed and dated informed consent.

        Exclusion Criteria:

          -  Inability to provide informed consent

          -  Earlier radiation therapy of the thorax

          -  Severe renal disease (patients in treatment with dialysis)
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Department of Cardiology, Orebro University Hospital</name>
      <address>
        <city>Orebro</city>
        <zip>70185</zip>
        <country>Sweden</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ole Frobert</last_name>
      <phone>46 19 602 54 13</phone>
      <email>ole.frobert@orebroll.se</email>
    </contact>
    <investigator>
      <last_name>Ole Frobert, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Sweden</country>
  </location_countries>
  <verification_date>September 2013</verification_date>
  <lastchanged_date>September 5, 2013</lastchanged_date>
  <firstreceived_date>August 27, 2013</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University Hospital Orebro</investigator_affiliation>
    <investigator_full_name>Ole Frobert</investigator_full_name>
    <investigator_title>MD, PhD</investigator_title>
  </responsible_party>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Sodium phosphate</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
